NCT01224886Recruiting
Age and Insulin Resistance
In French AGIR Means to Get Into Action. This is the Generic Title of Our Study.
Source: ClinicalTrials.gov · Last updated 5 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Insulin resistance is a crucial factor for the development of type 2 diabetes and a major health problem for older adults. It is the principal mechanism by which obesity is considered to increase the risk for type 2 diabetes and is a key feature of the metabolic syndrome. The elevated prevalence of obesity and type 2 diabetes in the older population has important consequences on the morbidity and mortality as well as on the economic burden on society. Controversy currently exists as to whether or not aging contributes to insulin resistance. Many potential factors confound the association between aging and insulin resistance, including obesity and physical inactivity. Ectopic lipid depositions, defined as an excess accumulation of triglycerides in non adipose tissues such as in the liver (intrahepatic lipids) and within the muscle fibers (intramyocellular lipids), are positively associated with obesity and insulin resistance. Furthermore, the accumulation of intracellular lipids is often cited as being a key determinant in the underlying mechanisms of insulin resistance. In addition of playing an important role in obesity and type 2 diabetes, these ectopic fat depositions are also observed in common conditions such as aging and physical inactivity. The intervention trial will test in skeletal muscle, liver and heart of sedentary obese volunteers, normal weight volunteers and masters athletes, the overall hypotheses that exercise improvement of fat oxidation capacity and/or decrease of damaging fat metabolites is a primary factor that predicts the improvement in insulin resistance.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 14 Oct 2010
- Start date
- Oct 2010
- Primary completion date
- Dec 2028
- Lead sponsor
- University of Lausanne
- Diseases
- Obesity
- NCT number
- NCT01224886
What you commit to
- Study type: Interventional
- Planned participants: 150
- From Oct 2010 to the primary completion date, Dec 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent hormone replacement therapy
Other illness
- Contraindication to moderate exercise or clinical conditions precluding from joining an exercise program, such as clinically significant cardiovascular disease, peripheral vascular disease, uncontrolled hypertension, neurological or orthopedic disease
- Known diabetes
- Severe anemia or lipid disturbances, hepatic or renal disease
- Recent history of cancer
- Known allergy to lidocaine or other local anesthetic
Lab values
- Known drugs to affect glucose homeostasis such as nicotinic acid, glucocorticoids
Other
- Recent weight loss or weight gain
- Hypothyroidism
- Positive stress test
- Active alcohol or substance abuse
Who the study is looking for
- Age 60-80
- Sedentary or highly trained
- BMI 18-40
- Non-Smoker
- Normal glucose tolerance or impaired glucose tolerance
- Willingness to comply with the protocol
Age in the registry: 60 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Bern Coordinator of this site? Confirm its status | Bern | Switzerland | Active, not recruiting |
| UNIL and CHUV Coordinator of this site? Confirm its status | Lausanne | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.